Cowen analyst, Ken Cacciatore, reiterated his Outperform rating on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) after Q1 was in-line and operations were on track.

The analyst stated "We continue to believe that this is emerging as one of the cleaner growth stories due to: (1) the increasing likelihood that the Xyrem franchise will be extended via new formulations (once-nightly) beyond 2023; (2) the launch of JZP-110, a likely $750MM+ long duration product; (3) growth via Defitilio, Vyxeos and Erwinaze; and (4) business development".

No change to the price target of $190.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $158.35 yesterday.